MX2017005644A - Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas. - Google Patents

Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.

Info

Publication number
MX2017005644A
MX2017005644A MX2017005644A MX2017005644A MX2017005644A MX 2017005644 A MX2017005644 A MX 2017005644A MX 2017005644 A MX2017005644 A MX 2017005644A MX 2017005644 A MX2017005644 A MX 2017005644A MX 2017005644 A MX2017005644 A MX 2017005644A
Authority
MX
Mexico
Prior art keywords
trypanosoma cruzi
cruzi
polypeptides
detecting
amino acid
Prior art date
Application number
MX2017005644A
Other languages
English (en)
Inventor
Roessler Dieter
Upmeier Barbara
Zarnt Toralf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14192004.1A external-priority patent/EP3018479A1/en
Priority claimed from EP15161274.4A external-priority patent/EP3072902A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017005644A publication Critical patent/MX2017005644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a variantes de antígenos JL7 que son apropiados para la detección de anticuerpos contra Trypanosoma cruzi (que causa la enfermedad de Chagas) en una muestra biológica aislada. Estos antígenos comprenden una secuencia de aminoácidos JL7 específica, la secuencia específica JL7 consiste de dos copias de la SEC ID NO. 2, en donde cada una de las dos copias tiene una identidad de aminoácidos de por lo menos el 90% a la SEC ID NO.2 y en donde ningunas secuencias de amino ácidos cruzi Trypanosoma específicos están presentes en el polipéptido. La invención también se refiere a una composición de polipéptidos útiles para la detección de anticuerpos contra Trypanosoma cruzi que comprende el antígeno JL7 caracterizado anteriormente junto con por lo menos uno de polipéptidos 1F8, cruzipaína, KMP-11 y PAR-2 de T. cruzi. Por otra parte, se refiere a un método para producir antígeno JL7 así como a métodos de diagnóstico para la detección de anticuerpos de T. cruzi utilizando el polipéptido JL7. Además, la invención se refiere a un kit de reactivos que comprende los polipéptidos JL7 o composición de polipéptidos de Trypanosoma cruzi.
MX2017005644A 2014-11-06 2015-11-04 Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas. MX2017005644A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192004.1A EP3018479A1 (en) 2014-11-06 2014-11-06 Antigen composition for detecting Chagas disease
EP15161274.4A EP3072902A1 (en) 2015-03-27 2015-03-27 Recombinant Trypanosoma cruzi JL7 antigen variants and their use for detecting Chagas disease
PCT/EP2015/075692 WO2016071393A1 (en) 2014-11-06 2015-11-04 Recombinant trypanosoma cruzi jl7 antigen variants and their use for detecting chagas disease

Publications (1)

Publication Number Publication Date
MX2017005644A true MX2017005644A (es) 2017-06-29

Family

ID=54478742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005644A MX2017005644A (es) 2014-11-06 2015-11-04 Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.

Country Status (7)

Country Link
US (1) US10228370B2 (es)
EP (1) EP3215849B1 (es)
JP (2) JP7173732B2 (es)
CN (1) CN107074921B (es)
BR (1) BR112017007592A2 (es)
MX (1) MX2017005644A (es)
WO (1) WO2016071393A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023182521A1 (ja) * 2022-03-25 2023-09-28 積水メディカル株式会社 免疫学的測定用試薬及び免疫学的測定方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228372B1 (en) 1997-04-15 2001-05-08 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
EP0976763B1 (en) 1998-07-30 2003-11-05 Innogenetics N.V. Antigens and immunoassays for diagnosing Chagas' disease
PE20050942A1 (es) 2003-12-04 2005-11-10 Louis V Kirchhoff Polipeptidos recombinantes para diagnosticar la infeccion con el trypanosoma cruzi
EP2182979A4 (en) 2007-07-30 2010-09-08 Univ Georgia DIAGNOSTIC TEST OF TRYPANOSOMA CRUZI INFECTION
WO2009158729A2 (en) * 2008-06-27 2009-12-30 The Infectious Disease Research Institute Inc. Compounds and methods for diagnosis and treatment of chagas disease
WO2010142829A1 (es) 2009-06-12 2010-12-16 Consejo Superior De Investigaciones Científicas (Csic) Método de obtención de datos útiles para el diagnóstico diferencial de la enfermedad de chagas, y para evaluar la respuesta al tratamiento
FR2952649B1 (fr) * 2009-11-13 2012-05-04 Univ Victor Segalen Bordeaux 2 Applications therapeutiques et diagnostiques contre les trypanosomoses animales africaines

Also Published As

Publication number Publication date
JP2017533913A (ja) 2017-11-16
CN107074921A (zh) 2017-08-18
EP3215849A1 (en) 2017-09-13
CN107074921B (zh) 2021-03-16
JP2021098746A (ja) 2021-07-01
JP7356467B2 (ja) 2023-10-04
BR112017007592A2 (pt) 2018-02-27
EP3215849B1 (en) 2018-12-19
US10228370B2 (en) 2019-03-12
US20170248598A1 (en) 2017-08-31
JP7173732B2 (ja) 2022-11-16
WO2016071393A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
WO2018085599A3 (en) Methods of nucleic acid sample preparation for immune repertoire sequencing
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
TN2018000325A1 (en) ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123.
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
MY173004A (en) Mycobacterial antigen vaccine
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
MX2016010791A (es) Inmunoterapia con multiples objetivos dirigida por biomarcadores.
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
MY196874A (en) Humanized anti-basigin antibodies and the use thereof
WO2016014612A3 (en) Compositions and methods for the diagnosis of rheumatoid arthritis
EP4300101A3 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
BR112017022205A2 (pt) anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
SG10201903424RA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
MX2017005650A (es) Composicion de antigeno para detectar enfermedad de chagas.
WO2015200833A3 (en) COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2)
MX2019003288A (es) Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis.
MX2016012525A (es) Anticuerpo anti-grpr, proceso de obtencion, proceso de deteccion, uso de anticuerpo, kit y construccion genetica.
AR100427A1 (es) PROTEÍNAS DE UNIÓN A ANTÍGENO DE HER1 QUE SE UNEN A LA HORQUILLA b DE HER1

Legal Events

Date Code Title Description
FG Grant or registration